Anti-hEGFR-hIgA2

InvivoGen Kontakt z doradcą
Human EGFR (cetuximab) antibody - Human IgA2
Anti-hEGFR-hIgA2

Anti-hEGFR-hIgA2 features the constant region of the human IgA2 isotype and the variable region of cetuximab. Cetuximab is a chimeric human/mouse IgG1 monoclonal antibody that targets epidermal growth factor receptor (EGFR), a cell surface receptor overexpressed in many types of cancer. EGFR is activated by binding specific ligands, including epidermal growth factor and transforming growth factor-α. Activation of EGFR promotes cell proliferation and survival, as well as angiogenesis, leading to tumor growth and metastasis. Binding of cetuximab to EGFR blocks ligand/receptor binding and induces receptor internalization and subsequent degradation. Consequently, cetuximab blocks downstream pathways which regulate cell growth and angiogenesis. In addition, cetuximab induces cell death through antibody-dependent cell-mediated cytotoxicity (ADCC) [1, 2]. Cetuximab has been approved by the FDA for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck [3].
Anti-hEGFR-hIgA2 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with peptide M.

References:

  1. Kurai J. et al., 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 3(5):1552-61.
  2. Kimura H. et al., 2007. Antibodydependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98(8):1275-80.
  3. Vincenzi B. et al., 2010. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 10(1):80-95.

Podobne produkty

Anti-gp75

Anti-gp75

InvivoGen
Więcej
pTRIOZ Collection

pTRIOZ Collection

InvivoGen
Więcej
Anti-hEGFR-hIgG1NQ

Anti-hEGFR-hIgG1NQ

InvivoGen
Więcej